CK Nutraceuticals partners with Kunpoong to distribute chitosan oligosaccharide

44d7d4b0-0873-4616-99a0-0f68e30897ffarticleimage.jpg

28 Sep 2017 --- South Korea’s Kunpoong Bio Co. Ltd., a global operator in the chitosan oligosaccharide market, has appointed Toronto-based CK Nutraceuticals (CK) as its exclusive North America sales, marketing and distribution partner for its Go2Ka1 ingredient (branded as KitoMax in North America).

CK focuses on supplying functional and nutritional ingredients for the functional food, beverage, dietary supplement and sports nutrition markets in North America. Kunpoong, based in Seoul, produces and supplies chitosan oligosaccharide for use in pharmaceutical, food and agricultural applications.

Under the terms of the multi-year agreement, CK is to promote advanced glucose management nutraceutical KitoMax to its extensive base of dietary supplement clients in both the US and Canada.

Solution backed by science
“We see increasing consumer and industry interest in the blood glucose management category, and we believe that KitoMax is a safe, effective and scientifically-proven solution in this important health category,” Michael Chernyak, President of CK Nutraceuticals, tells NutritionInsight.

KitoMax is a patent-pending chitosan-oligosaccharide produced using advanced enzymatic technology, the CK press release states. It has a well-defined mechanism of action, and is supported by three published clinical studies that demonstrate meaningful blood glucose control benefits.

CK adds that the applications of KitoMax include capsules, tablets, nutrition bars, stick packs, powdered drink mixes, gummies and more.

Several compelling structure/function claims have been defined for KitoMax in the US, and in Canada it has received a license from Health Canada with the approved claims “Helps to support healthy glucose metabolism,” “Helps to maintain healthy glucose metabolism,” “Helps maintain healthy blood sugar levels” and “Helps support healthy blood sugar levels.”

Chernyak also points to three published clinical trials that demonstrate: immediate effect on post-prandial blood glucose levels post-meal (sugar and bread/starch); and long-term administration effect, especially in reducing HbA1c and waist circumference.

“What is also important to note is that the long-term clinical trial was performed in a pre-diabetic population that was receiving no other medical intervention (to our knowledge, this is the only report of a natural product reducing HbA1c in pre-diabetic population),” Chernyak adds.

There is a team of scientists who collectively have more than 100 publications in the field of Type 2 diabetes prevention on board, Chernyak points out.

“We are thrilled to collaborate with Kunpoong Bio on this terrific ingredient, which we believe is very timely,” says Chernyak. “Our mission is to supply our North American clients with superior raw materials that are backed by scientific research of the very highest quality, and KitoMax certainly fits the bill.”

To contact our editorial team please email us at editorial@cnsmedia.com

Related Articles

Nutrition & Health News

Infant nutrition (part 1): Challenges in feeding the first 1,000 days

18 Jun 2018 --- The World Health Organization (WHO) solidly recommends breastfeeding for infants. However, there are situations – medical, situational or personal – that necessitate good quality breast milk substitutes (BMS), such as formulas. In a bid to produce a formula that is closest in composition to human breast milk, manufacturers face a range of unique R&D challenges. In this two-part series on Infant Nutrition, NutritionInsight speaks to a number of key suppliers and experts about these challenges.

Nutrition & Health News

OptiBiotix begins application development for fibrous sweeteners in agreement with global dairy brand

05 Jun 2018 --- Tackling diets that can be high in sugar but low in fiber, OptiBiotix has produced SweetBiotix: fibers that are natural, high-intensity sweeteners. The life sciences company has signed an evaluation agreement to explore the potential of the SweetBiotix technology with an unnamed dairy company. The company is said to have an annual turnover of US$10 billion and the SweetBiotix technology is hoped to reduce the sugar content in a range of its dairy products.

Nutrition & Health News

Gut health (part 2): Probiotic growth to continue

30 May 2018 --- As knowledge of the gut microbiome increases, probiotics have experienced a huge surge in popularity. Not only can they boost the overall health of the microbiome but specific strains can provide answers to some medical conditions. In this report, NutritionInsight notes the importance of scientific research for probiotic strains, growing market applications and novel delivery forms, as informed by Ganeden, Kerry, Fonterra and Anlit. In part one of the gut health series, functional fiber was the focus.

Nutrition & Health News

DuPont attains US green light on HMO infant nutrition solution

17 May 2018 --- DuPont Nutrition & Health’s CARE4U human milk oligosaccharide (HMO) is now Generally Recognized as Safe (GRAS) for use in infant and toddler formula following a “No Objection” letter from the US Food and Drug Administration.

Nutrition & Health News

FrieslandCampina’s human milk oligosaccharide ingredient obtains EU approval and GRAS status

09 May 2018 --- FrieslandCampina DOMO’s new human milk oligosaccharide (HMO) ingredient, 2’-fucosyllactose (2’-FL), has been officially certified for use in infant formula in both European and US markets. The ingredient has received EU novel food approval and achieved GRAS (Generally Recognized as Safe) status from the Food and Drug Administration (FDA) in the US. The company reports that these authorizations are an important step forward in the plan of FrieslandCampina to launch its first HMO by the end of the year.

More Articles
URL : http://www.nutritioninsight.com:80/news/ck-nutraceuticals-partners-with-kunpoong-to-distribute-chitosan-oligosaccharide.html